GE updates Signa platform
The latest evolution of GE Healthcare's Signa HD x (high definition x) platform offers MR pulse sequences that overcome barriers to diagnostic scans in some difficult-to-image patients. The xt version, shown at the RSNA meeting, features two major innovations: 3D Cube and Ideal.
The latest evolution of GE Healthcare's Signa HD x (high definition x) platform offers MR pulse sequences that overcome barriers to diagnostic scans in some difficult-to-image patients. The xt version, shown at the RSNA meeting, features two major innovations: 3D Cube and Ideal. 3D Cube's capture of submillimeter isotropic voxels allows the viewing of a volumetric data set in any plane and the visualization of lesions as small as 2 mm. Ideal improves image clarity through uniform fat suppression and handling multiple contrasts from fat, water, and the two combined, both in-phase and out-of-phase. It also reduces or eliminates artifacts due to chemical shift of metal implants, such as orthopedic screws or dental work, and eliminates misregistration between fat and water.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
